큐라클

365270KOSDAQ자연과학 및 공학 연구개발업

40.7 / 100

Reference Date: 2026-04-13

Financial Score9.5 / 40

News Sentiment14.2 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR raises overvaluation concerns, Revenue is on a declining trend. Plunged 25.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Curacle is a biotech venture company developing innovative therapeutics targeting endothelial dysfunction, leveraging its proprietary platforms Solvadys and Eagles to advance first-in-class drug candidates such as CU06, CU71, and CU01. CU06, a retinal disease treatment, demonstrated vision improvement in Phase 2a trials, while collaborations with MapTics have expanded its antibody-based pipeline.

Number of Employees

31people

Average Salary

81.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

8.23Industry Average 3.820.0Point

2.2x industry avg (risky)

ROE

-54.03Industry Average -32.113.5Point

1.7x industry avg (good)

Debt Ratio

9.08Industry Average 7.522.0Point

Higher than industry avg (caution)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼91.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼25.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -40.6% (declining, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 1Negative 0Average Sentiment Score 70

Neutral
‘관리종목’ 한숨 돌린 큐라클, 임상 환견 못 구해 ‘동물 신약’ 흔....
큐라클은 관리종목 지정을 피하기 위해 대성팜텍을 인수했으나, 반려동물 신부전 치료제 임상 환견 모집에 난항을 겪고 있어 미래 먹거리 확보에 불확실성이 존재합니다.

Detailed Momentum

52-week position6.0Point

52w upper range (64%)

Current 13,930Won52-week high 19,71052-week low 3,650

1-month return0.0Point

1m -25.31% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral투자판단관련주요경영사항(임상시험결과) (CU011001 당뇨병성 신증치료제 식품의약품안전처 임상 2b상 CSR 결과)2026-04-02
Neutral주식매수선택권부여에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral감사보고서제출2026-03-18
Neutral사업보고서 (2025.12)2026-03-18